NASDAQ:PBLS Parabilis Medicines Q3 2026 Earnings Results & Report $28.62 -1.03 (-3.47%) As of 09:50 AM Eastern Parabilis Medicines beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.36 versus the -$0.40 consensus estimate, while revenue was $2.11 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market Opens Parabilis Medicines EPS ResultsActual EPS-$0.36Consensus EPS -$0.40Beat/MissBeat by +$0.04One Year Ago EPSN/AParabilis Medicines Revenue ResultsActual Revenue$2.11 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Parabilis Medicines Q3 2026 Earnings FAQ Did Parabilis Medicines beat earnings estimates for Q3 2026? Parabilis Medicines (NASDAQ:PBLS) reported earnings of -$0.36 per share for Q3 2026, beating the consensus estimate of -$0.40. The report was announced on Thursday, November 12, 2026. What was Parabilis Medicines' revenue for Q3 2026? Parabilis Medicines reported revenue of $2.11 million for Q3 2026. Parabilis Medicines Earnings HeadlinesParabilis Medicines Q3 Loss Narrows47 minutes ago | marketscreener.comMParabilis Medicines Q3 2026: Revenue Came In 323% Above Estimates47 minutes ago | 247wallst.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 12 at 1:00 AM | Behind the Markets (Ad)Parabilis Medicines: Q3 earnings snapshot47 minutes ago | msn.comEarnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q3 Revenue $2.1M47 minutes ago | marketscreener.comMParabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates3 hours ago | globenewswire.comSee More Parabilis Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Parabilis Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Parabilis Medicines and other key companies, straight to your email. Email Address About Parabilis MedicinesParabilis Medicines (NASDAQ:PBLS) is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.View Parabilis Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
